MSI2 blocking compounds and methods of their use
MSI2 blocking compounds are developed to address the lack of effective therapeutic agents for MSI2-related cancers by binding and inhibiting MSI2 activity, showing promise in reducing tumor formation and growth.
Patent Information
- Application Number
- PCT/US2026/027305
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
There are no therapeutic agents that can effectively bind and block Musashi 2 (MSI2), an RNA-binding protein implicated in various cancers, limiting treatment options for conditions such as pancreatic cancer, ovarian cancer, breast cancer, and others.
Development of MSI2 blocking compounds, including Formula IA, IB, II, HA, IIB, and IIC, which are designed to bind and inhibit MSI2 activity, potentially reducing tumor formation and growth.
The MSI2 blocking compounds demonstrate effective binding to MSI2, inhibiting its function and reducing tumorsphere formation in pancreatic cancer cells, suggesting potential therapeutic efficacy against MSI2-related cancers.
Smart Images

Figure IMGF000001_0001 
Figure IMGF000002_0001 
Figure IMGF000002_0002
Abstract
Description
Atty Docket No. 92573-A-PCT 93597 / 7710MSI2 BLOCKING COMPOUNDS AND METHODS OF THEIR USECROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of U.S. Provisional Application No. 63 / 802,749, filed May 9, 2025, the contents of which are hereby incorporated by reference.BACKGROUND
[0002] Musashi 2 (MSI2) is an RNA-binding protein that regulates mRNA translation of numerous intracellular targets and has been found to play an important role in the development of several cancers, including pancreatic cancer, ovarian cancer, breast cancer, lung cancer, colorectal cancer, malignant glioma, hepatic cancer, prostate cancer, bladder cancer, oral or esophageal cancer, gastric cancer, thyroid cancer, and hematological malignancies (e.g., a leukemia or lymphoma), among others. At this time, are no therapeutic agents that can effectively bind and block MSI2. As such, discovery of such agents is needed.SUMMARY
[0003] The present disclosure provides a Musashi 2 (MSI2) blocking compound ofFormula IAor stereoisomer, ester, or salt thereof,or of Formula IB4916-6765-7898v.lAtty Docket No. 92573-A-PCT93597 / 7710or stereoisomer, ester, or salt thereof,wherein R2is selected from the group consisting of hydrogen, a C1-6 alkyl, a cycloakyl, a heterocycloalkyl, an aryl, or a heteroaryl, and wherein the non-hydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxylate group, and a thio group.
[0004] The present disclosure also provides a Musashi 2 (MSI2) blocking compound of Formula IIpl_l3or stereoisomer, ester, or salt thereof, wherein any one or more of R3, R4, R5, R6, or R7can be C or N; andwherein R8is selected from the group consisting of hydrogen, a C1-6 alkyl, a cycloakyl, a heterocycloalkyl, an aryl, or a heteroaryl, and wherein the non-hydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxylate group, and a thio group.BRIEF DESCRIPTION OF THE DRAWINGS
[0005] FIG. 1: MST Binding Assay: MSI2-RNA. Significant binding of target RNA to MSI2 is detected in both TRIC and Spectral Shift readout modes according to some embodiments.24916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0006] FIG 2: MSI2-RNA Binding Confirmation of Tycho according to some embodiments. A strong shift in the melting temperature of MSI2 is observed, indicating target RNA binding and stabilization of MSI2.
[0007] FIG. 3: MSI2-RNA MST Dose Response Analysis according to some embodiments. Both Spectral Shift and TRIC readout modes show nM binding, as expected given the affinity of the target RNA for MSI2.
[0008] FIG. 4: MSI2-Gossypol MST Dose Repose Analysis. The Spectral Shift readout mode shows low pM binding of gossypol to MSI2 according to some embodiments; binding is not detected in the TRIC readout mode.
[0009] FIG. 5: MST Dose Response Analysis. The Spectral Shift readout mode shows pM binding of PCS2192 to MSI2 according to some embodiments.
[0010] FIG. 6: Murine pancreatic cancer cells (KPC tumor cells) were cultured in the presence of 90 pM compound for 10 days, after which tumorsphere formation was measured according to some embodiments. Vehicle (DMSO) treated tumor cells are represented by the gray bars identified as “Veh.Ctl.”
[0011] FIG. 7: Human pancreatic cancer cells (FG cells) were cultured in the presence of compound at the indicated concentration for 7 days, after which tumorsphere formation was measured according to some embodiments. Vehicle (DMSO) treated tumor cells are represented by the gray bars identified as “Veh.Ctl.”
[0012] FIG. 8: Human pancreatic cancer cells (FG cells) were cultured in the presence of compound at the indicated concentration for 7 days, after which tumorsphere formation was measured. Vehicle (DMSO) treated tumor cells are represented by the gray bars.
[0013] FIG. 9: Shows new designs based on candidate PCS2192, according to some embodiments.
[0014] Fig. 10: Schematic of CETSA strategy to evaluate intracellular binding of inhibitors to MSI2. Adapted from Tolvanen, T. A. (2022). Current Advances in CETSA. Front Mol Biosci, 9, 866764.34916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0015] Fig. 11: CETSA was performed with HEK-293T cells that were treated with DMSO or PCS2192 (20 pM, 50 uM or 100 pM). Above: Western blot analysis of soluble Msi2 in each sample. The band intensity at 48°C and 50°C increases in a dose-dependent manner, suggesting binding between Msi2 and PCS2192 within the cells, leading to stabilization of Msi2.
[0016] Fig. 12: Re-run of DMSO and 50 pM PCS2192-treated samples from Experiment 1. Band intensity of soluble Msi2 in 50 pM-treated sample was higher than band intensity of soluble Msi2 in DMSO-treated sample at both 48°C and 50°C (see plot on next Fig.).
[0017] Fig. 13: 293T CETSA + PCS2192
[0018] Fig. 14: DMSO and 50 pM PCS2192-treated samples from Experiment 1 re-run on the same gel to permit direct comparison of band intensities at 48°C. Band intensity of soluble Msi2 in 50 pM-treated sample was higher than band intensity of soluble Msi2 in DMSO-treated sample.
[0019] Fig. 15: Schematic of LightSwitch (Active Motif, Inc.) strategy to measure the activity of MSI2 inhibitors within a living cell.
[0020] Fig. 16: HEK-293T cells were transfected with Luciferase-Numb 3’-UTR reporter plasmid and treated with DMSO or PCS2192 (20, 50 or 100 uM). Luminescence was normalized to cell viability and fold change was calculated relative to the results from DMSO-treated samples.
[0021] Fig. 17: HEK-293T cells were transfected with Luciferase-Numb 3’-UTR reporter plasmid and treated with DMSO or PCS3375 (20, 50 or 100 uM). Luminescence was normalized to cell viability and fold change was calculated relative to the results from DMSO-treated samples.DETAILED DESCRIPTION
[0022] The present disclosure provides a Musashi 2 (MSI2) blocking compound of44916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 Formula IAor stereoisomer, ester, or salt thereof,or of Formula IBor stereoisomer, ester, or salt thereof,wherein R2is selected from the group consisting of hydrogen, a C1-6 alkyl, a cycloakyl, a heterocycloalkyl, an aryl, or a heteroaryl, and wherein the non-hydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxyl or carboxylate group, and a thio group.
[0023] In some embodiments in the MSI2 blocking compound of Formula IA or Formula IB, the carbonyl group is an alkylcarbonyl.
[0024] In some embodiments in the MSI2 blocking compound of Formula IA or Formula IB, the carboxyl or carboxylate group is an alkylcarboxyl or alkylcarboxylate.
[0025] In some embodiments in the MSI2 blocking compound of Formula IA or Formula IB, the thio group is an alkylthio.
[0026] In some embodiments, the MSI2 blocking compound is54916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0027] In some embodiments, the MSI2 blocking compound isCH3O—0 0HCH3 or stereoisomer, ester, or salt thereof.
[0028] The present disclosure also provides a Musashi 2 (MSI2) blocking compound of Formula IICH3R6\ / ' ' X V- p4N — << ;R3^ \\~-'7r8CH3 or stereoisomer, ester, or salt thereof, wherein any one or more of R3, R4, R5, R6, or R7can be C or N; andwherein R8is selected from the group consisting of hydrogen, a C1-6 alkyl, a cycloakyl, a heterocycloalkyl, an aryl, or a heteroaryl, and wherein the non-hydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxyl or carboxylate group, and a thio group.
[0029] In some embodiments in the MSI2 blocking compound of Formula II, the carbonyl group is an alkylcarbonyl.
[0030] In some embodiments in the MSI2 blocking compound of Formula II, the carboxyl or carboxylate group is an alkylcarboxyl or alkylcarboxylate.
[0031] In some embodiments in the MSI2 blocking compound of Formula II, the thiol group is an alkylthiol.
[0032] In some embodiments the MSI2 blocking compound comprises a compound of Formula HA4916-6765-7898v.lAtty Docket No. 92573-A-PCT93597 / 7710CH3 or stereoisomer, ester, or salt thereof, wherein R8is selected from the group consisting of hydrogen, a C1-6 alkyl, a cycloakyl, a heterocycloalkyl, an aryl, or a heteroaryl, and wherein the non-hydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxyl or carboxylate group, and a thio group.
[0033] In some embodiments in the MSI2 blocking compound of Formula HA, the carbonyl group is an alkylcarbonyl.
[0034] In some embodiments in the MSI2 blocking compound of Formula HA, the carboxyl or carboxylate group is an alkylcarboxyl or alkylcarboxylate.
[0035] In some embodiments in the MSI2 blocking compound of Formula HA, the thiol group is an alkylthiol.
[0036] In some embodiments the MSI2 blocking compound isQH3OHCH3or stereoisomer, ester, or salt thereof.
[0037] In some embodiments the MSI2 blocking compound isor stereoisomer, ester, or salt thereof.74916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0038] In some embodiments the MSI2 blocking compound isNNH or stereoisomer, ester, or salt thereof.
[0039] In some embodiments the MSI2 blocking compound comprises a compound of Formula IIBCH3 or stereoisomer, ester, or salt thereof, wherein R8is selected from the group consisting of hydrogen, a C1-6 alkyl, a cycloakyl, a heterocycloalkyl, an aryl, or a heteroaryl, and wherein the non-hydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxyl or carboxylate group, and a thio group.
[0040] In some embodiments in the MSI2 blocking compound of Formula IIB, the carbonyl group is an alkylcarbonyl.
[0041] In some embodiments in the MSI2 blocking compound of Formula IIB, the carboxyl or carboxylate group can be an alkylcarboxyl or alkylcarboxylate.
[0042] In some embodiments in the MSI2 blocking compound of Formula IIB, the thiol group is an alkylthiol.
[0043] In some embodiments, the MSI2 blocking compound is4916-6765-7898v.lAtty Docket No. 92573-A-PCT93597 / 7710CH3 or stereoisomer, ester, or salt thereof.
[0044] In some embodiments, the MSI2 blocking compound comprises a compound of Formula IICCH3 or stereoisomer, ester, or salt thereof, wherein R8is selected from the group consisting of hydrogen, a C1-6 alkyl, a cycloakyl, a heterocycloalkyl, an aryl, or a heteroaryl, and wherein the non-hydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxyl or carboxylate group, and a thio group.
[0045] In some embodiments in the MSI2 blocking compound of Formula IIC, the carbonyl group is an alkylcarbonyl.
[0046] In some embodiments in the MSI2 blocking compound of Formula IIC, the carboxyl or carboxylate group is an alkylcarboxyl or alkylcarboxylate.
[0047] In some embodiments in the MSI2 blocking compound of Formula IIC, the thiol group is an alkylthiol.
[0048] In some embodiments, the MSI2 blocking compound is4916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0049] The present invention also provides a pharmaceutical composition comprising an MSI2 blocking compound described herein, further comprising a carrier. The carrier can be a pharmaceutically-acceptable and / or physiologically acceptable carrier.
[0050] The present invention also provides a pharmaceutical composition comprising an MSI2-blocking PROTAC described herein and a carrier. The carrier can be a pharmaceutically-acceptable and / or physiologically acceptable carrier.
[0051] The present invention also provides the use of an MSI2 blocking compound described herein for the treatment of a cancer. The present invention also provides the use of an MSI2-blocking PROTAC described herein for the treatment of a cancer.
[0052] The present invention also provides a method of treating a cancer comprising administering the MSI2-blocking compound to a subject. The present invention also provides a method of treating a cancer comprising administering a MSI2-blocking PROTAC described herein to a subject.
[0053] In some embodiments of the use or method, the cancer is pancreatic cancer, ovarian cancer, breast cancer, lung cancer, colorectal cancer, malignant glioma, hepatic cancer, prostate cancer, bladder cancer, oral or esophageal cancer, gastric cancer, thyroid cancer, or a hematological malignancy.
[0054] In some embodiments, the use or method comprises wherein the MSI2 blocking compound is part of a pharmaceutical composition.
[0055] A method for blocking or reducing the formation of a tumor, the method comprising contacting a tumor cell or a population of tumor cells with an MSI2 blocking compound. A method for blocking or reducing the formation of a tumor, the method comprising contacting a tumor cell or a population of tumor cells with an MSI2-blocking PROTAC described herein.
[0056] A method for blocking or reducing the growth of a tumor, the method comprising contacting a tumor cell or a population of tumor cells with an MSI2 blocking compound described herein. A method for blocking or reducing the growth of a tumor, the method104916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 comprising contacting a tumor cell or a population of tumor cells with an MSI2-blocking PROTAC described herein.
[0057] A method for inducing regression of a tumor, the method comprising contacting a tumor cell or a population of tumor cells with an MSI2 blocking compound described herein. A method for inducing regression of a tumor, the method comprising contacting a tumor cell ora population of tumor cells with an MSI2-blocking PROTAC described herein.
[0058] In some embodiments of the methods herein, the tumor cell or population of tumor cells are pancreatic cancer cells, ovarian cancer cells, breast cancer cells, lung cancer cells, colorectal cancer cells, malignant glioma cells, hepatic cancer cells, prostate cancer cells, bladder cancer cells, oral or esophageal cancer cells, gastric cancer cells, thyroid cancer cells, or cells of a hematological malignancy (e,g., leukemia cells or lymphoma cells).
[0059] In some embodiments of uses or methods herein, the MSI2 blocking compound is part of a pharmaceutical composition. In some embodiments of uses or methods herein, the MSI2-blocking PROTAC described herein is part of a pharmaceutical composition.
[0060] A method of inhibiting MSI2, optionally intracellularly, comprising administering an MSI2 blocking compound described herein to a cell having MSI2 activity. A method of inhibiting MSI2, optionally intracellularly, comprising administering an MSI2-blocking PROTAC described herein to a cell having MSI2 activity.
[0061] The present invention also provides a PROTAC as disclosed herein or a PROTAC comprising any one of the MSI2-blocking compounds disclosed herein.
[0062] In some embodiments, the PROTAC comprises a molecule comprising an E3 ligase ligand, a linker, and a compound disclosed herein, or a building block and compound disclosed herein, or a complete PROTAC described herein.
[0063] In some embodiments, the PROTAC comprises a molecule as set forth in Table 6. In some embodiments, the PROTAC comprises a molecule as set forth in Table 6, excepting that the PCS3375 compound is replaced by another MSI2 blocking compound set forth herein.114916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 Definitions
[0064] All numerical designations, e.g., pH, temperature, time, concentration, and molecular weight, including ranges, are approximations which are varied (+) or (-) by increments of 1.0 or 0.1, as appropriate, or alternatively by a variation of + / - 15 %, or alternatively 10%, or alternatively 5%, or alternatively 2%. It is to be understood, although not always explicitly stated, that all numerical designations are preceded by the term “about.” It is to be understood that such range format is used for convenience and brevity and should be understood flexibly to include numerical values explicitly specified as limits of a range, but also to include all individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly specified. For example, a ratio in the range of about 1 to about 200 should be understood to include the explicitly recited limits of about 1 and about 200, but also to include individual ratios such as about 2, about 3, and about 4, and sub-ranges such as about 10 to about 50, about 20 to about 100, and so forth. It also is to be understood, although not always explicitly stated, that the reagents described herein are merely exemplary and that equivalents of such are known in the art.
[0065] It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a light-harvesting molecule” includes a plurality of light-harvesting molecules.
[0066] Ranges recited herein are intended as continuous ranges, including every value between the minimum and maximum values recited, as well as any ranges that can be formed by such values. Also disclosed herein are any and all ratios (and ranges of any such ratios) that can be formed by dividing a disclosed numeric value into any other disclosed numeric value. Accordingly, the skilled person will appreciate that many such ratios, ranges, and ranges of ratios can be unambiguously derived from the numerical values presented herein, and in all instances such ratios, ranges, and ranges of ratios represent various embodiments of the present technology. It is understood that where a numerical range is recited herein, the present invention contemplates each integer between, and including, the upper and lower limits, unless otherwise stated.124916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0067] The term “about,” as used herein when referring to a measurable value such as an amount or concentration and the like, is meant to encompass variations of 20%, 10%, 5%, 1%, 0.5%, or even 0.1% of the specified amount.
[0068] Also as used herein, “and / or” refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (“or”).
[0069] As used herein, the terms “molecule”, “complex”, “compound”, and “product” are used interchangeably, and are intended to refer to a chemical entity, whether in the solid, liquid, or gaseous phase, and whether in a crude mixture or purified and isolated.
[0070] As used herein, “salt” refers to derivatives of the disclosed compounds or chemical structures wherein the parent complex is modified by making acid or base salts thereof.
[0071] As used herein, the term “solvate” refers to a physical association of a compound of this disclosure with one or more solvent molecules, whether organic or inorganic.
[0072] Compounds or chemical structures of the present technology, free form and salts thereof, may exist in multiple tautomeric forms, in which hydrogen atoms are transposed to other parts of the molecules and the chemical bonds between the atoms of the molecules are consequently rearranged. It should be understood that all tautomeric forms, insofar as they may exist, are included within the disclosure. The compounds of the subject invention may have spontaneous tautomeric forms. In cases wherein compounds may exist in tautomeric forms, such as keto-enol tautomers, each tautomeric form is contemplated as being included within this invention whether existing in equilibrium or predominantly in one form.
[0073] Throughout the specification and the appended claims, a given chemical formula or structure shall encompass all stereo and optical isomers and racemates thereof where such isomers exist. Unless otherwise indicated, all chiral (enantiomeric and diastereomeric) and racemic forms are within the scope of the disclosure. Many geometric 134916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 isomers of C=N double bonds, ring systems, and the like can also be present in the complexes, and all such stable isomers are contemplated in the present disclosure.
[0074] Except where otherwise specified, if the structure of a compound of this invention includes an asymmetric carbon atom, it is understood that the compound occurs as a racemate, racemic mixture, and isolated single enantiomer. All such isomeric forms of these compounds are expressly included in this invention. Except where otherwise specified, each stereogenic carbon may be of the R or S configuration. It is to be understood accordingly that the isomers arising from such asymmetry (including all enantiomers and diastereomers) are included within the scope of this invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis, such as those described in "Enantiomers, Racemates and Resolutions" by J. Jacques, A. Collet and S. Wilen, Pub. John Wiley & Sons, NY, 1981. For example, the resolution may be carried out by preparative chromatography on a chiral column.
[0075] As used herein, unless specified otherwise, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Thus, Ci -Cn as in “Ci-Cn alkyl" is defined to include groups having 1, 2 , n-1 or n carbons in a linear or branched arrangement. Alkyl can be taken to include monovalent or multivalent hydrocarbon groups. Examples specifically include, but are not limited to methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, isopropyl, isobutyl, sec-butyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, and so on. An embodiment can be C1-C12 alkyl, C2-C12 alkyl, C3-C12 alkyl, C4-C12 alkyl and so on. In certain embodiments, the hydrocarbon group contains 1 to 30 carbons. In certain embodiments, the hydrocarbon group contains 1 to 20 carbons. In certain embodiments, the hydrocarbon group contains 1 to 12 carbons. In certain embodiments, the hydrocarbon group contains 1 to 6 carbons.
[0076] As used herein, unless specified otherwise, the term "cycloalkyl" means an alkyl which contains at least one ring. In certain embodiments, a cycloalkyl is a saturated cycloalkyl group. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl,144916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl and cyclododecyl. In certain embodiments, the hydrocarbon chain contains 1 to 30 carbons. In certain embodiments, the hydrocarbon group contains 1 to 20 carbons. In certain embodiments, the hydrocarbon group contains 1 to 12 carbons. In certain embodiments, the hydrocarbon group contains 1 to 6 carbons.
[0077] As used herein, unless specified otherwise, the term "heterocycloalkyl" means a cycloalkyl wherein at least one ring atom is a non-carbon atom. Examples of the noncarbon ring atom include, but are not limited to, S, O and N. Examples of heterocycloalkyl groups include, but are not limited to, 1,2-oxathiolane, 1,3-oxathiolane, azete, azetidine, aziridine, azirine, diazete, diazetidine, diazinane, diazine, diaziridine, diazirine, dioxane, dioxazole, dioxetane, dioxete, dioxine, dioxirane, dioxolane, dithiane, dithiazole, dithietane, dithiete, dithiin, dithiolane, dithiole, furan, furazan, hexazine, imidazole (imidazoline), imidazolidine, isothiazole, isothiazolidine, isoxathiole, isoxazole, morpholine, oxadiazole, oxane, oxatetrazole, oxathiane, oxathiin, oxathiole (oxathioline), oxazine, oxaziridine, oxazirine / / oxirane, oxazole (oxazoline), oxazolidine isoxazolidine, oxetane, oxete, oxirene, pentazole, piperidine, pyran, pyrazole (pyrazoline), pyrazolidine, pyridine, pyridinium cation, pyrrole, pyrrolidine, pyrylium cation, tetrahydrofuran, tetrahydrothiophene, tetrahydrothiophene, tetrazine, tetrazole, thiadiazole, thiane, thiatetrazole, thiazine, thiazole (thiazoline), thiazolidine, thietane, thiete, thiirane, thiirene, thiomorpholine, thiophene, thiopyran, thiopyrylium cation, triazinane, triazine, triazoles, trioxane, trithiane.
[0078] As used herein, unless specified otherwise, the term “alkoxy" or "alkoxyl" means an alkyl or cycloalkyl group as described above attached through an oxygen bridge. Examples of alkoxyl include, but are not limited to, -OCH3, or -O-alkyl.
[0079] As used herein, unless specified otherwise, the term "alkylthio" means an alkyl, cycloalkyl or heterocycloalkyl, which contains one or more sulfur atoms. Examples of alkylthio include, but are not limited to, -CH2-SH, -SCH3, -S-alkyl, -alkyl-SH, -alkyl-S-alkyl-, wherein the two alkyls can be the same or different.
[0080] As used herein, unless specified otherwise, the term "alkylcarbonyl" means an alkyl, cycloalkyl or heterocycloalkyl, which contains one or more carbonyl groups. Examples 154916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 of alkylcarbonyl group include, but are not limited to, aldehyde group (-R'-C(O)-H), ketone group (-R'-C(O)-R"), carboxylic acid group (R'-COOH), ester group (-R"-COO-R'), carboxamide, (-R'"-COO-N(R')R"), enone group (-R""-C(O)-C(R')=C(R")R'"), acyl halide group (-R'-C(O)-X) and acid anhydride group (-R"-C(O)-O-C(O)-R'), wherein R', R", R'" and R"" are the same or different alkyl, cycloalkyl, or heterocycloalkyl.
[0081] As used herein, unless specified otherwise, the term "alkylcarboxylate" means an alkyl, cycloalkyl or heterocycloalkyl, which contains one or more protonated or deprotonated carboxylic acid groups. Examples of a Iky I carboxy I ate groups include, but are not limited to, carboxylate group (R’-COO ) wherein R' is an alkyl, cycloalkyl, or heterocycloalkyl.
[0082] As used herein, "monocycle" or “monocyclic” includes any stable polyatomic carbon ring of up to 10 atoms and may be unsubstituted or substituted. Examples of such non-aromatic monocycle elements include but are not limited to: cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. Examples of such aromatic monocycle elements include but are not limited to: phenyl.
[0083] As used herein, "bicycle" or “bicyclic” includes any stable polyatomic carbon ring of up to 10 atoms that is fused to a polyatomic carbon ring of up to 10 atoms with each ring being independently unsubstituted or substituted. Examples of such non-aromatic bicycle elements include but are not limited to: decahydronaphthalene. Examples of such aromatic bicycle elements include but are not limited to: naphthalene.
[0084] As used herein, unless specified otherwise, the term “aryl” means a chemical structure comprising one or more aromatic rings, wherein at least one ring is aromatic, and may be unsubstituted or substituted. In certain embodiments, the ring atoms are all carbon. In certain embodiments, one or more ring atoms are non-carbon, e.g. oxygen, nitrogen, or sulfur ("heteroaryl"). Examples of aryl include, without limitation, phenyl, benzyl, naphthalenyl, anthracenyl, pyridyl, quinoyl, isoquinoyl, pyrazinyl, quinoxalinyl, acridinyl, pyrimidinyl, quinazolinyl, pyridazinyl, cinnolinyl, imidazolyl, benzimidazolyl, purinyl, indolyl, furanyl, benzofuranyl, isobenzofuranyl, pyrrolyl, indolyl, isoindolyl, thiophenyl,164916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 benzothiophenyl, pyrazolyl, indazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, thiaxolyl, quanidino and benzothiazolyl.
[0085] The terms “substitution”, “substituted” and “substituent” refer to a functional group as described above in which one or more bonds to a hydrogen atom contained therein are replaced by a bond to non-hydrogen or non-carbon atoms, provided that normal valencies are maintained and that the substitution results in a stable compound. Substituted groups also include groups in which one or more bonds to a carbon(s) or hydrogen(s) atom are replaced by one or more bonds, including double or triple bonds, to a heteroatom. Examples of substituent groups include the functional groups described above, and halogens (i.e., F, Cl, Br, and I); alkyl groups, such as methyl, ethyl, n-propyl, isopropryl, n-butyl, tert-butyl, and trifluoromethyl; hydroxyl; alkoxy groups, such as methoxy, ethoxy, n-propoxy, and isopropoxy; aryloxy groups, such as phenoxy; arylalkyloxy, such as benzyloxy (phenylmethoxy) and p-trifluoromethylbenzyloxy (4-trifluoromethylphenylmethoxy); heteroaryloxy groups; sulfonyl groups, such as trifluoromethanesulfonyl, methanesulfonyl, and p-toluenesulfonyl; nitro, nitrosyl; mercapto; sulfanyl groups, such as methylsulfanyl, ethylsulfanyl and propylsulfanyl; cyano; amino groups, such as amino, methylamino, dimethylamino, ethylamino, and diethylamino; and carboxyl. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally. By independently substituted, it is meant that the (two or more) substituents can be the same or different. A group is noted as “optionally substituted”, the group may or may not contain non-hydrogen substituents.
[0086] For the foregoing embodiments, each embodiment disclosed herein is contemplated as being applicable to each of the other disclosed embodiments.
[0087] As used herein, all headings are simply for organization and are not intended to limit the disclosure in any manner. The content of any individual section may be equally applicable to all sections. All combinations of the various elements disclosed herein are within the scope of the invention.174916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0088] Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.
[0089] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
[0090] Examples are provided below to facilitate a more complete understanding of the invention. The following examples illustrate the exemplary modes of making and practicing the invention. However, the scope of the invention is not limited to specific embodiments disclosed in these Examples, which are for purposes of illustration only.
[0091] In some embodiments, a pharmaceutically acceptable salt of any of the above compounds is provided. In some embodiments, an ester of any of the above compounds is provided. In some embodiments, an enantiomer of any of the above compounds is provided.
[0092] In some embodiments, a package or composition comprising any of the above compounds is provided.
[0093] In some embodiments, a salt of the compound of the present invention is used in any of the above methods, uses, packages or compositions. In some embodiments, a pharmaceutically acceptable salt of the compound of the present invention is used in any of the above methods, uses, packages or compositions. In some embodiments, an ester of the compound of the present invention is used in any of the above methods, uses, packages or184916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 compositions. Any of the above compounds may be used in any of the disclosed methods, uses, packages or pharmaceutical compositions.
[0094] Any of the compounds used in the disclosed methods, uses, packages or pharmaceutical compositions may be replaced with any other compound disclosed in the present invention. Any of the above generic compounds may be used in any of the disclosed methods, uses, packages or compositions.
[0095] As used herein, "treating" means inhibiting, slowing, halting, or reversing the progression of a disease or infection. Treating may also mean improving one or more symptoms of a disease or infection.
[0096] The compounds of the present invention include all hydrates, solvates, and complexes of the compounds used by this invention. If a chiral center or another form of an isomeric center is present in a compound of the present invention, all forms of such isomer or isomers, including enantiomers and diastereomers, are intended to be covered herein. Compounds containing a chiral center may be used as a racemic mixture, an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone. The compounds described in the present invention are in racemic form or as individual enantiomers. The enantiomers can be separated using known techniques, such as those described in Pure and Applied Chemistry 69, 1469-1474, (1997) IUPAC. In cases in which compounds have unsaturated carbon-carbon double bonds, both the cis (Z) and trans (E) isomers are within the scope of this invention.
[0097] In the compound structures depicted herein, hydrogen atoms are not shown for carbon atoms having less than four bonds to non-hydrogen atoms. However, it is understood that enough hydrogen atoms exist on said carbon atoms to satisfy the octet rule.
[0098] It is understood that the structures described in the embodiments of the methods hereinabove can be the same as the structures of the compounds described hereinabove.
[0099] The subject invention is also intended to include all isotopes of atoms occurring on the compounds disclosed herein. Isotopes include those atoms having the same atomic 194916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14.
[0100] It will be noted that any notation of a carbon in structures throughout this application, when used without further notation, are intended to represent all isotopes of carbon, such as12C,13C, or14C. Furthermore, any compounds containing13C or14C may specifically have the structure of any of the compounds disclosed herein.
[0101] It will also be noted that any notation of a hydrogen in structures throughout this application, when used without further notation, are intended to represent all isotopes of hydrogen, such as1H,2H, or3H. Furthermore, any compounds containing2H or3H may specifically have the structure of any of the compounds disclosed herein.
[0102] This invention also provides isotopic variants of the compounds disclosed herein, including wherein the isotopic atom is2H and / or wherein the isotopic atom13C. Accordingly, in the compounds provided herein hydrogen can be enriched in the deuterium isotope. It is to be understood that the invention encompasses all such isotopic forms.
[0103] Isotopically-labeled compounds can generally be prepared by conventional techniques known to those skilled in the art using appropriate isotopically-labeled reagents in place of the non-labeled reagents employed.
[0104] In the compounds used in the method of the present invention, the substituents may be substituted or unsubstituted, unless specifically defined otherwise.
[0105] In the compounds used in the method of the present invention, alkyl, heteroalkyl, haloalkyl, monocycle, bicycle, aryl, heteroaryl, carbocycle, and heterocycle groups can be further substituted by replacing one or more hydrogen atoms with alternative non-hydrogen groups. These include, but are not limited to, halo, hydroxy, mercapto, amino or amine, carboxy, cyano, carbamoyl and aminocarbonyl and aminothiocarbonyl.
[0106] It is understood that substituents and substitution patterns on the compounds used in the method of the present invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by 204916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 techniques known in the art from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results.
[0107] The term "alkenyl" refers to a non-aromatic hydrocarbon radical, straight or branched, containing at least 1 carbon to carbon double bond, and up to the maximum possible number of non-aromatic carbon-carbon double bonds may be present. Thus, C2-Cn alkenyl is defined to include groups having 1, 2...., n-1 or n carbons. For example, "C2-Ce alkenyl" means an alkenyl radical having 2, 3, 4, 5, or 6 carbon atoms, and at least 1 carbon-carbon double bond, and up to, for example, 3 carbon-carbon double bonds in the case of a Ce alkenyl, respectively. Alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl. As described above with respect to alkyl, the straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted if a substituted alkenyl group is indicated. An embodiment can be C2-C12 alkenyl, C3-C12 alkenyl, C4-C12 alkenyl and so on.
[0108] The term "alkynyl" refers to a hydrocarbon radical straight or branched, containing at least 1 carbon to carbon triple bond, and up to the maximum possible number of non-aromatic carbon-carbon triple bonds may be present. Thus, C2-Cn alkynyl is defined to include groups having 1, 2...., n-1 or n carbons. For example, "C2-C6 alkynyl" means an alkynyl radical having 2 or 3 carbon atoms, and 1 carbon-carbon triple bond, or having 4 or 5 carbon atoms, and up to 2 carbon-carbon triple bonds, or having 6 carbon atoms, and up to 3 carbon-carbon triple bonds. Alkynyl groups include ethynyl, propynyl and butynyl. As described above with respect to alkyl, the straight or branched portion of the alkynyl group may contain triple bonds and may be substituted if a substituted alkynyl group is indicated. An embodiment can be a C2-Cn alkynyl. An embodiment can be C2-C12 alkynyl, C3-C12 alkynyl, C4-C12 alkynyl and so on.
[0109] “Alkylene”, “alkenylene” and “alkynylene” shall mean, respectively, a divalent alkane, alkene and alkyne radical, respectively. It is understood that an alkylene, alkenylene, and alkynylene may be straight or branched. An alkylene, alkenylene, and alkynylene may be unsubstituted or substituted.214916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0110] As used herein “hetero-" as a prefix refers to atoms other than carbon such that the group within the term is comprised of one or more heteroatoms along with one or more carbon atoms. Preferred heteroatoms include N, 0, and / or S, including N-oxides, sulfur oxides, and dioxides. Examples of “hetero-" elements include but are not limited to: heteroaryl, heterocycle, heteromonocycle, and the like.
[0111] As used herein, "heteroalkyl" includes both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms and at least 1 heteroatom within the chain or branch.
[0112]
[0113] As used herein, the term “polycycle” or “polycyclic” refers to any stable polyatomic unsaturated or partially unsaturated multiple fused ring structures, which may be unsubstituted or substituted. Examples of such non-aromatic monocycle elements include but are not limited to: cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. Examples of such aromatic monocycle elements include but are not limited to: phenyl.
[0114] The term “haloalkyl” refers to alkyl groups as described above wherein one or more bonds to hydrogen contained therein are replaced by a bond to a halogen as described herein. It is understood that a “haloalkyl” group is connected to a core molecule through a bond from the alkyl group and that the halogen group acts as a substituent on the alkyl group. Examples of haloalkyl moieties include, but are not limited to, trifluoromethyl, difluoromethyl, chloroethyl, 1,2-dibromoethyl, 2,2-diflorocyclobutyl, 4,4-diflorocyclohexyl, and the like.
[0115] The term “aminoalkyl” refers to alkyl groups as described above wherein one or more bonds to hydrogen contained therein are replaced by a bond to an amine or amino group as described herein. It is understood that a “aminoalkyl” group is connected to a core molecule through a bond from the alkyl group and that the amine or amino group acts as a substituent on the alkyl group. Examples of aminoalkyl moieties include, but are not limited to, ethylamine, N-methyl propylamine, N-methyl azetidine, 4-aminocyclohexyl, and the like.224916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0116] The term “arylalkyl” refers to alkyl groups as described above wherein one or more bonds to hydrogen contained therein are replaced by a bond to an aryl group as described above. It is understood that an “arylalkyl” group is connected to a core molecule through a bond from the alkyl group and that the aryl group acts as a substituent on the alkyl group. Examples of arylalkyl moieties include, but are not limited to, benzyl (phenylmethyl), p-trifluoromethylbenzyl (4-trifluoromethylphenylmethyl), 1 -phenylethyl, 2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl and the like.
[0117] The term "heteroaryl", as used herein, represents a stable monocyclic, bicyclic or polycyclic ring of up to 10 atoms in each ring, wherein at least one ring is aromatic and contains from 1 to 4 heteroatoms selected from the group consisting of 0, N and S. Bicyclic aromatic heteroaryl groups include phenyl, pyridine, pyrimidine or pyridizine rings that are (a) fused to a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom; (b) fused to a 5- or 6-membered aromatic (unsaturated) heterocyclic ring having two nitrogen atoms; (c) fused to a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom together with either one oxygen or one sulfur atom; or (d) fused to a 5-membered aromatic (unsaturated) heterocyclic ring having one heteroatom selected from 0, N or S. Heteroaryl groups within the scope of this definition include but are not limited to: benzimidazolyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, quinolyl, furanyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, isoxazoline, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, acridinyl, carbazolyl, quinoxalinyl, pyrrazolyl, indolyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, isoxazolyl, isothiazolyl, furanyl, thienyl, benzothienyl, benzofuranyl, quinolinyl, isoquinolinyl, oxazolyl, isoxazolyl, indolyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, or pyrrolyl. In cases where the heteroaryl substituent is bicyclic and one ring is non-aromatic or contains no heteroatoms, it is understood that attachment is via the aromatic ring or via the heteroatom containing ring, respectively. If the heteroaryl contains nitrogen atoms, it is understood that the corresponding N-oxides thereof are also encompassed by this definition.234916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0118] The term “heteroarylalkyl” refers to alkyl groups as described above wherein one or more bonds to hydrogen contained therein are replaced by a bond to an heteroaryl group as described above. It is understood that an “heteroarylalkyl” group is connected to a core molecule through a bond from the alkyl group and that the heteroaryl group acts as a substituent on the alkyl group. Examples of heteroarylalkylmoieties include, but are not limited to, -CH2-(C5H4N), -CH2-CH2-(C5H4N) and the like.
[0119] The term "heterocycle", “heterocyclyl”, or “heterocyclic” refers to a mono- or poly-cyclic ring system which can be saturated or contains one or more degrees of unsaturation and contains one or more heteroatoms. Preferred heteroatoms include N, 0, and / or S, including N-oxides, sulfur oxides, and dioxides. Preferably the ring is three to tenmembered and is either saturated or has one or more degrees of unsaturation. More preferably the ring is three to four-membered and has one or more degrees of unsaturation. The heterocycle may be unsubstituted or substituted, with multiple degrees of substitution being allowed. Such rings may be optionally fused to one or more of another "heterocyclic" ring(s), heteroaryl ring(s), aryl ring(s), or cycloalkyl ring(s). Examples of heterocycles include, but are not limited to, aziridine, azirine, diazirine, oxirane, thiirane, azetidine, oxetane, thetane, tetrahydrofuran, pyran, 1,4-dioxane, 1,3-dioxane, piperidine, piperazine, pyrrolidine, morpholine, thiomorpholine, tetrahydrothiopyran, tetrahydrothiophene, 1,3-oxathiolane, and the like.
[0120] The term “carbocycle” or “carbocyclic” refers to a monocyclic ring system which can be saturated or contains one or more degrees of unsaturation and contains exclusively carbon atoms within the ring. However, it is understood that enough hydrogen atoms exist on said carbon atoms to satisfy the octet rule. Preferably the ring is three to ten-membered and is either saturated or has one or more degrees of unsaturation. More preferably the ring is five to six-membered and has one or more degrees of unsaturation. The carbocycle may be unsubstituted or substituted, with multiple degrees of substitution being allowed. Such rings may be optionally fused to one or more of another "carbocyclic" ring(s), heteroaryl ring(s), aryl ring(s), or cycloalkyl ring(s). Examples of carbocycles include, but are not limited to, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, benzene, and the like.244916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0121] The alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl substituents may be substituted or unsubstituted, unless specifically defined otherwise. In the compounds of the present invention, alkyl, alkenyl, alkynyl, aryl, heterocyclyl, cycloalkyl, and heteroaryl groups can be further substituted by replacing one or more hydrogen atoms with alternative non-hydrogen groups. These include, but are not limited to, halo, hydroxy, mercapto, amino, carboxy, cyano and carbamoyl.
[0122] As used herein, the term “halogen” or “halo” refers to any atom which is a member of the halogen group of elements. Preferably consisting of the group F, Cl, Br, and I.
[0123] The term “ester” is intended to a mean an organic compound containing the R-O-CO-R’ group.
[0124] In choosing the compounds of the present invention, one of ordinary skill in the art will recognize that the various substituents, i.e. Ri , R2, etc. are to be chosen in conformity with well-known principles of chemical structure connectivity.
[0125] The compounds used in the method of the present invention may be prepared by techniques known in organic synthesis and familiar to a practitioner ordinarily skilled in the art. However, these may not be the only means by which to synthesize or obtain the desired compounds.
[0126] The compounds used in the method of the present invention may be prepared by techniques described in Vogel’s Textbook of Practical Organic Chemistry, A.L Vogel, A.R. Tatchell, B.S. Furnis, A. J. Hannaford, P.W.G. Smith, (Prentice Hall) 5th Edition (1996), March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Michael B. Smith, Jerry March, (Wiley-lnterscience) 5th Edition (2007), and references therein, which are incorporated by reference herein. However, these may not be the only means by which to synthesize or obtain the desired compounds.
[0127] The various R groups attached to the aromatic rings of the compounds disclosed herein may be added to the rings by standard procedures, for example those set forth in Advanced Organic Chemistry: Part B: Reactions and Synthesis, Francis Carey and254916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 Richard Sundberg, (Springer) 5th ed. Edition. (2007), the content of which is hereby incorporated by reference.
[0128] Another aspect of the invention comprises a compound used in the method of the present invention as a pharmaceutical composition.
[0129] As used herein, the term “pharmaceutically active agent”, “pharmaceutically active ingredient”, “pharmaceutically active component”, “active ingredient”, “active agent”, or “active component” means any substance or compound suitable for administration to a subject and furnishes biological activity or other direct effect in the treatment, cure, mitigation, diagnosis, or prevention of disease, or affects the structure or any function of the subject. Pharmaceutically active agents include, but are not limited to, substances and compounds described in the Physicians’ Desk Reference (PDR Network, LLC; 64th edition; November 15, 2009) and “Approved Drug Products with Therapeutic Equivalence Evaluations” (U.S. Department Of Health And Human Services, 30th edition, 2010), which are hereby incorporated by reference. Pharmaceutically active agents which have pendant carboxylic acid groups may be modified in accordance with the present invention using standard esterification reactions and methods readily available and known to those having ordinary skill in the art of chemical synthesis. Where a pharmaceutically active agent does not possess a carboxylic acid group, the ordinarily skilled artisan will be able to design and incorporate a carboxylic acid group into the pharmaceutically active agent where esterification may subsequently be carried out so long as the modification does not interfere with the pharmaceutically active agent’s biological activity or effect.
[0130] The compounds of the present invention may also form salts with basic amino acids such a lysine, arginine, etc. and with basic sugars such as N-methylglucamine, 2-amino-2 -deoxyglucose, etc. and any other physiologically non-toxic basic substance.
[0131] As used herein, “administering” an agent may be performed using any of the various methods or delivery systems well known to those skilled in the art. The administering can be performed, for example, orally, parenterally, intraperitoneally, intravenously, intraarterially, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery,264916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 subcutaneously, intraadiposally, intraarticularly, intrathecally, into a cerebral ventricle, intraventicularly, intratumorally, into cerebral parenchyma or intraparenchchymally.
[0132] The compounds used in the method of the present invention may be administered in various forms, including those detailed herein. The treatment with the compound may be a component of a combination therapy or an adjunct therapy, i.e. the subject or patient in need of the drug is treated or given another drug for the disease in conjunction with one or more of the instant compounds. This combination therapy can be sequential therapy where the patient is treated first with one drug and then the other or the two drugs are given simultaneously. These can be administered independently by the same route or by two or more different routes of administration depending on the dosage forms employed.
[0133] The dosage of the compounds administered in treatment will vary depending upon factors such as the pharmacodynamic characteristics of a specific chemotherapeutic agent and its mode and route of administration; the age, sex, metabolic rate, absorptive efficiency, health and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment being administered; the frequency of treatment with; and the desired therapeutic effect.
[0134] Techniques and compositions for making dosage forms useful in the present invention are described in the following references: 7 Modern Pharmaceutics, Chapters 9 and 10 (Banker & Rhodes, Editors, 1979); Pharmaceutical Dosage Forms: Tablets (Lieberman et al., 1981); Ansel, Introduction to Pharmaceutical Dosage Forms 2nd Edition (1976); Remington's Pharmaceutical Sciences, 17th ed. (Mack Publishing Company, Easton, Pa., 1985); Advances in Pharmaceutical Sciences (David Ganderton, Trevor Jones, Eds., 1992); Advances in Pharmaceutical Sciences Vol. 7. (David Ganderton, Trevor Jones, James McGinity, Eds., 1995); Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms (Drugs and the Pharmaceutical Sciences, Series 36 (James McGinity, Ed., 1989); Pharmaceutical Particulate Carriers: Therapeutic Applications: Drugs and the Pharmaceutical Sciences, Vol 61 (Alain Rolland, Ed., 1993); Drug Delivery to the Gastrointestinal Tract (Ellis Norwood Books in the Biological Sciences. Series in274916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 Pharmaceutical Technology; J. G. Hardy, S. S. Davis, Clive G. Wilson, Eds.); Modem Pharmaceutics Drugs and the Pharmaceutical Sciences, Vol 40 (Gilbert S. Banker, Christopher T. Rhodes, Eds.). All of the aforementioned publications are incorporated by reference herein.
[0135] Tablets may contain suitable binders, lubricants, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents. For instance, for oral administration in the dosage unit form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, gelatin, agar, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
[0136] The compounds used in the method of the present invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamallar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines. The compounds may be administered as components of tissue-targeted emulsions.
[0137] The compounds used in the method of the present invention may also be coupled to soluble polymers as targetable drug carriers or as a prodrug. Such polymers include polyvinylpyrrolidone, pyran copolymer, polyhydroxylpropylmethacrylamide-phenol, polyhydroxyethylasparta-midephenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone,284916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.
[0138] The compounds used in the method of the present invention may also be administered in intranasal form via use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will generally be continuous rather than intermittent throughout the dosage regimen.
[0139] Specific examples of pharmaceutically acceptable carriers and excipients that may be used to formulate oral dosage forms of the present invention are described in U.S. Pat. No. 3,903,297 to Robert, issued Sept. 2, 1975. Techniques and compositions for making dosage forms useful in the present invention are described-in the following references: 7 Modern Pharmaceutics, Chapters 9 and 10 (Banker & Rhodes, Editors, 1979); Pharmaceutical Dosage Forms: Tablets (Lieberman et al., 1981); Ansel, Introduction to Pharmaceutical Dosage Forms 2nd Edition (1976); Remington's Pharmaceutical Sciences, 17th ed. (Mack Publishing Company, Easton, Pa., 1985); Advances in Pharmaceutical Sciences (David Ganderton, Trevor Jones, Eds., 1992); Advances in Pharmaceutical Sciences Vol 7. (David Ganderton, Trevor Jones, James McGinity, Eds., 1995); Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms (Drugs and the Pharmaceutical Sciences, Series 36 (James McGinity, Ed., 1989); Pharmaceutical Particulate Carriers: Therapeutic Applications: Drugs and the Pharmaceutical Sciences, Vol 61 (Alain Rolland, Ed., 1993); Drug Delivery to the Gastrointestinal Tract (Ellis Norwood Books in the Biological Sciences. Series in Pharmaceutical Technology; J. G. Hardy, S. S. Davis, Clive G. Wilson, Eds.); Modem Pharmaceutics Drugs and the Pharmaceutical Sciences, Vol 40 (Gilbert S. Banker, Christopher T. Rhodes, Eds.). All of the aforementioned publications are incorporated by reference herein.
[0140] The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, powders, and chewing gum; or in liquid dosage forms, such as elixirs,294916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 syrups, and suspensions, including, but not limited to, mouthwash and toothpaste. It can also be administered parentally, in sterile liquid dosage forms.
[0141] Solid dosage forms, such as capsules and tablets, may be enteric-coated to prevent release of the active ingredient compounds before they reach the small intestine. Materials that may be used as enteric coatings include, but are not limited to, sugars, fatty acids, proteinaceous substances such as gelatin, waxes, shellac, cellulose acetate phthalate (CAP), methyl acrylate-methacrylic acid copolymers, cellulose acetate succinate, hydroxy propyl methyl cellulose phthalate, hydroxy propyl methyl cellulose acetate succinate (hypromellose acetate succinate), polyvinyl acetate phthalate (PVAP), and methyl methacrylate-methacrylic acid copolymers.
[0142] The compounds and compositions of the invention can be coated onto stents for temporary or permanent implantation into the cardiovascular system of a subject.
[0143] Each embodiment disclosed herein is contemplated as being applicable to each of the other disclosed embodiments. Thus, all combinations of the various elements described herein are within the scope of the invention.
[0144] This invention will be better understood by reference to the Experimental Details which follow, but those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention as described more fully in the claims which follow thereafter.
[0145] “And / or” as used herein, for example, with option A and / or option B, encompasses the separate embodiments of (i) option A, (ii) option B, and (iii) option A plus option B.
[0146] All combinations of the various elements described herein are within the scope of the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
[0147] Definitions: The terms used in this specification generally have their ordinary meanings in the art, within the context of this invention and the specific context where each term is used. Certain terms are discussed below, or elsewhere in the specification, to 304916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 provide additional guidance to the practitioner in describing the methods of the invention and how to use them. Moreover, it will be appreciated that the same thing can be said in more than one way. Consequently, alternative language and synonyms may be used for any one or more of the terms discussed herein, nor is any special significance to be placed upon whether or not a term is elaborated or discussed herein. Synonyms for certain terms are provided. A recital of one or more synonyms does not exclude the use of the other synonyms. The use of examples anywhere in the specification, including examples of any terms discussed herein, is illustrative only, and in no way limits the scope and meaning of the invention or any exemplified term. Likewise, the invention is not limited to its preferred embodiments.
[0148] The term “subject” as used in this application means a mammal. Mammals include canines, felines, rodents, bovine, equines, porcines, ovines, and primates including humans. Thus, the invention can be used in human medicine or also in veterinary medicine, e.g., to treat companion animals, farm animals, laboratory animals in zoological parks, and animals in the wild. The invention is particularly desirable for human medical applications. In a preferred embodiment the subject is a human.
[0149] The terms “therapeutically effective amount” or "amount effective to" encompasses, unless otherwise indicated, an amount sufficient to ameliorate or inhibit a symptom or sign of the medical condition. An effective amount for a particular subject may vary depending on factors such as the condition being treated, the overall health of the patient, the method route and dose of administration and the severity of side effects. An effective amount can be the maximal dose or dosing protocol that avoids significant side effects or toxic effects.Musashi 2 blocking compounds:
[0150] Provided herein are compounds that can bind to and block the activity of RNA-binding protein Musashi 2 (MSI2), referred to herein as “MSI2 blocking compounds.”
[0151] In some embodiments, the MSI2 blocking compound is PCS2192 or a derivative thereof, including stereoisomers, esters, and salts thereof:314916-6765-7898v.lAtty Docket No. 92573-A-PCT93597 / 7710PCS2192
[0152] In some embodiments, the MSI2 blocking compound is PCS3152 ora derivative thereof, including stereoisomers, esters, and salts thereof:PCS3152
[0153] After identifying a new series of compounds with promising Intellectual Property (IP) through a conformation-driven approach, an original hit (PCS2192) was chosen and the leading compound (PCS3152) for an Absorption, Distribution, Metabolism, and Excretion (ADME) study to understand their physico-chemical properties. This information serves as a guide for further optimization. Additionally, the Single-Dose Pharmacokinetics (SDPK) in mice for the leading compound was assessed, exploring its potential as a drug candidate. Both compounds underwent various ADME assays, and the leading compound underwent SDPK study, all conducted at Pharmaron China. The results are detailed below in Example 1.
[0154] Table 1 of Example 1 below illustrates the ADME properties of PCS2192 and PCS3152, indicating their robust solubility and favorable plasma protein binding. Both compounds exhibit commendable stability in Liver Microsomes for both human and mouse species, with PCS2192 demonstrating superior stability in LM. Notably, in the Caco2 permeability assay, PCS2192 displays exceptional permeability without any observed efflux issues. In comparison, PCS3152 exhibits relatively lower permeability and a discernible efflux ratio. Nevertheless, the permeability of PCS3152 remains within an acceptable range.324916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0155] The SDPK summary for compound PCS3152 in Table 2 of Example 1 (mouse data) indicates outstanding bioavailability, reasonable Vss, good clearance, and acceptable AUC. The initial SDPK data suggests the viability of this compound series.
[0156] Given that PCS2192 demonstrated excellent ADME properties, it serves as a promising starting point for further exploration. This may involve fine-tuning to discover additional viable compounds in a new series and novel scaffolds with favorable ADME properties.Musashi 2 blocking compounds derived from PCS2192 and PCS3152:
[0157] Provided herein are compounds that can bind to and block the activity of RNA-binding protein Musashi 2 (MSI2), referred to herein as “MSI2 blocking compounds.”
[0158] In accordance with the embodiments described herein, in some embodiments, the MSI2 blocking compound comprises a structure in accordance with Formula I below, including stereoisomers, esters, and salts thereof:'3N R Formula ICH3
[0159] In some embodiments, Formula I comprises a thiol, thioether, alcohol, or ether compound, wherein R1comprises -S-R2(Formula IA) or -O-R2(Formula IB), embodiments of which are disclosed below.
[0160] In certain embodiments, the MSI2 blocking compound is a sulfide or thiol having a structure in accordance with Formula I is a structure comprising Formula IA below, including stereoisomers, esters, and salts thereof:4916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710Formula IA
[0161] In some embodiments, R2is hydrogen, a C1-6 alkyl, cycloakyl, heterocycloalkyl, aryl, or heteroaryl, which the non-hydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxyl or carboxylate group, a thio group.
[0162] In some embodiments, wherein in the MSI2 blocking compound of Formula IA the carbonyl group is an alkylcarbonyl.
[0163] In some embodiments, wherein in the MSI2 blocking compound of Formula IA the carboxyl or carboxylate group is an alkylcarboxyl or alkylcarboxylate.
[0164] In some embodiments, wherein in the MSI2 blocking compound of Formula IA the thiol group is an alkylthiol.
[0165] In some embodiments, the MSI2 blocking compound is PCS2192 (WXHTS0063086), a Formula IA compound that has the following structure, including stereoisomers, esters, and salts thereof:CH3OH Formula IA Compound PCS2192 (WXHTS0063086)CH3
[0166] In some embodiments, the MSI2 blocking compound comprises an ether structure in accordance with Formula IB below, including stereoisomers, esters, and salts thereof:4916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710Formula IB
[0167] In some embodiments, R2is hydrogen, a C1-6 alkyl, cycloakyl, heterocycloalkyl, aryl, or heteroaryl, which the non-hydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxyl or carboxylate group, a thio group.
[0168] In some embodiments, wherein in the MSI2 blocking compound of Formula IB the carbonyl group is an alkylcarbonyl.
[0169] In some embodiments, wherein in the MSI2 blocking compound of Formula IB the carboxyl or carboxylate group is an alkylcarboxyl or alkylcarboxylate.
[0170] In some embodiments, wherein in the MSI2 blocking compound of Formula IB the thiol group is an alkylthiol.
[0171] In some embodiments, the MSI2 blocking compound is PBUE231, a Formula IB compound that has the following structure, including stereoisomers, esters, and salts thereof.Formula IB CompoundPBUE231
[0172] In some embodiments, the MSI2 blocking compound comprises a structure in accordance with Formula II below, including stereoisomers, esters, and salts thereof354916-6765-7898v.lAtty Docket No. 92573-A-PCT93597 / 7710
[0173] In some embodiments, any one or more of R3, R4, R5, R6, or R7can be C or N.
[0174] In some embodiments, the 5-membered ring is a heteroaryl.
[0175] In some embodiments, R3is N and R4, R5, R6, and R7are C.
[0176] In some embodiments, R4is N and R3, R5, R6, and R7are C.
[0177] In some embodiments, R5is N and R3, R4, R5, and R6are C.
[0178] In some embodiments, R6is N and R3, R4, R5, and R6are C.
[0179] In some embodiments, R7is N and R3, R4, R5, and R6are C.
[0180] In some embodiments, any two or more of R3, R4, R5, R6, or R7are N, and the remaining positions on the 5-carbon ring are C.
[0181] In some embodiments, R4and R5are N and the remaining positions on the 5-carbon ring are C.
[0182] In some embodiments, R8is hydrogen, a C1-6 alkyl, cycloakyl, heterocycloalkyl, aryl, or heteroaryl, which the non-hydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxyl or carboxylate group, a thio group.
[0183] In some embodiments, wherein in the MSI2 blocking compound of Formula II the carbonyl group is an alkylcarbonyl.
[0184] In some embodiments, wherein in the MSI2 blocking compound of Formula II the carboxyl or carboxylate group is an alkylcarboxyl or alkylcarboxylate.
[0185] In some embodiments, wherein in the MSI2 blocking compound of Formula II the thiol group is an alkylthiol.4916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0186] An accordance with such embodiments, in some aspects, the MSI2 blocking compound comprises a structure in accordance with Formula HA below, including stereoisomers, esters, and salts thereof.Formula IIA
[0187] In some embodiments, R8is hydrogen, a C1-6 alkyl, cycloakyl, heterocycloalkyl, aryl, or heteroaryl, which the non-hydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxyl or carboxylate group, a thio group.
[0188] In some embodiments, wherein in the MSI2 blocking compound of Formula HA the carbonyl group is an alkylcarbonyl.
[0189] In some embodiments, wherein in the MSI2 blocking compound of Formula HA the carboxyl or carboxylate group is an alkylcarboxyl or alkylcarboxylate.
[0190] In some embodiments, wherein in the MSI2 blocking compound of Formula HA the thiol group is an alkylthiol.
[0191] In some embodiments, the MSI2 blocking compound is PCS3380, a Formula IIB compound that has the following structure, including stereoisomers, esters, and salts thereof.Formula IIB CompoundPCS3380374916-6765-7898v.lAtty Docket No. 92573-A-PCT93597 / 7710
[0192] In some embodiments, the MSI2 blocking compound is PCS3375, a Formula IIA compound that has the following structure, including stereoisomers, esters, and salts thereof.Formula IIA CompoundPCS3375
[0193] In some embodiments, the MSI2 blocking compound is PCS3381, a Formula IIA compound that has the following structure, including stereoisomers, esters, and salts thereof.Formula IIA CompoundPCS3381
[0194] In such embodiments, the MSI2 blocking compound comprises a structure in accordance with Formula I IB below, including stereoisomers, esters, and salts thereof:4916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710Formula II BCH3
[0195] In some embodiments, R8is hydrogen, a C1-6 alkyl, cycloakyl, heterocycloalkyl, aryl, or heteroaryl, which the non-hydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxyl or carboxylate group, a thio group.
[0196] In some embodiments, wherein in the MSI2 blocking compound of Formula IIB the carbonyl group is an alkylcarbonyl.
[0197] In some embodiments, wherein in the MSI2 blocking compound of Formula IIB the carboxyl or carboxylate group is an alkylcarboxyl or alkylcarboxylate.
[0198] In some embodiments, wherein in the MSI2 blocking compound of Formula IIB the thiol group is an alkylthiol.
[0199] In some embodiments, the MSI2 blocking compound is PCS3380, a Formula IIB compound that has the following structure, including stereoisomers, esters, and salts thereof.Formula II B CompoundPCS3380
[0200] In other such embodiments, the MSI2 blocking compound comprises a structure in accordance with Formula I IC below, including stereoisomers, esters, and salts thereof:4916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710Formula IIC
[0201] In some embodiments, R8is hydrogen, a C1-6 alkyl, cycloakyl, heterocycloalkyl, aryl, or heteroaryl, which the non-hydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxyl or carboxylate group, a thio group.
[0202] In some embodiments, wherein in the MSI2 blocking compound of Formula IIB the carbonyl group is an alkylcarbonyl.
[0203] In some embodiments, wherein in the MSI2 blocking compound of Formula IIB the carboxyl or carboxylate group is an alkylcarboxyl or alkylcarboxylate.
[0204] In some embodiments, wherein in the MSI2 blocking compound of Formula IIB the thiol group is an alkylthiol.
[0205] In some embodiments, the MSI2 blocking compound is PH01629269, a Formula IIC compound that has the following structure, including stereoisomers, esters, and salts thereof.Formula IIC CompoundPH01629269
[0206] In some embodiments, a salt of the MSI2 blocking compounds disclosed herein is a pharmaceutically acceptable salt. As used herein, the term "pharmaceutically acceptable salt" means those salts of compounds of the present disclosure that are safe for application in a subject. Pharmaceutically acceptable salts include salts of acidic or basic groups present in compounds of the present disclosure, or have been modified by making 404916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 acid or base salts of the compounds. Pharmaceutically acceptable acid addition salts include, but are not limited to, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate, p-toluenesulfonate and pamoate (i.e., 1 ,11-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Certain compounds of the present disclosure can form pharmaceutically acceptable salts with various amino acids. Suitable base salts include, but are not limited to, aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, and diethanolamine salts. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as phenols; alkali or organic salts of acidic residues such as carboxylic acids. The salts can be made using an organic or inorganic acid. Such acid salts are chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, salicylates, ascorbates, and the like. Phenolate salts are alkali metal salts, sodium, potassium or lithium. The term "pharmaceutically acceptable salt" in this respect, refers to the relatively non-toxic, inorganic and organic acid or base addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or by separately reacting a purified compound of the invention in its free base or free acid form with a suitable organic or inorganic acid or base, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. For a review on pharmaceutically acceptable salts see BERGE ET AL., 66 J. PHARM. SCI. 1 - 19 (1977), incorporated herein by reference.
[0207] As used herein, the term "pharmaceutically acceptable acid" means acids that can form salts with compounds of the present disclosure that are safe for application in a subject. Examples of pharmaceutically acceptable acid include, but are not limited to, e.g. hydrochloride, hydrobromide, hydroiodide, nitric acid , sulfic acid, bisulfic acid, phosphoric 414916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 acid, phosphorous acid, phospheonic acid, isonicotinic acid, acetic acid, lactic acid, salicylic acid, citric acid, tartaric acid, pantothenic acid, bitartaric acid, ascorbic acid, succinic acid, maleic acid, gentisinic acid, fumaric acid, gluconic acid, glucaronic acid, saccharic acid, formic acid, benzoic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzensulfonic acid, p-toluenesulfonic acid and pamoic acid.Methods of Use:
[0208] The MSI2 blocking compounds described herein may have anti-tumorigenic activity and thus may be used in methods for preventing or treating a cancer. In some embodiments, the MSI2 blocking compounds are used to prevent or treat a cancer associated with MSI2 overexpression or MSI2 activity including, but not limited to pancreatic cancer, ovarian cancer, breast cancer, lung cancer, colorectal cancer, malignant glioma, hepatic cancer, prostate cancer, bladder cancer, oral or esophageal cancer, gastric cancer, thyroid cancer, or hematological malignancies (e,g., a leukemia or lymphoma). Such methods may include administering a MSI2 blocking compound to a subject.
[0209] In other embodiments, methods for blocking the formation of a tumor, blocking the growth of a tumor, or inducing regression of a tumor are provided. Such methods may include a step of contacting a tumor cell or a population of tumor cells with an MSI2 blocking compound, e.g., an MSI2 blocking compound described above and in the Examples below. In some methods, contacting a tumor cell or population of tumor cells occurs in vivo or in vitro.
[0210] In some embodiments the tumor cell or population of tumor cells are pancreatic cancer cells, ovarian cancer cells, breast cancer cells, lung cancer cells, colorectal cancer cells, malignant glioma cells, hepatic cancer cells, prostate cancer cells, bladder cancer cells, oral or esophageal cancer cells, gastric cancer cells, thyroid cancer cells, or cells of a hematological malignancy (e,g., a leukemia cells or lymphoma cells).
[0211] In certain embodiments, the MSI2 blocking compound is part of a pharmaceutical composition. In some aspects, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.424916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0212] The term "pharmaceutically acceptable carrier" as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting an MSI2 blocking compound from one location, body fluid, tissue, organ (interior or exterior), or portion of the body, to another location, body fluid, tissue, organ, or portion of the body, or for delivering the instant compounds to the animal or human. The carrier may be liquid or solid and is selected with the planned manner of administration in mind. Liposomes are also pharmaceutically acceptable carriers as are slow-release vehicles.
[0213] Each carrier is "pharmaceutically acceptable" in the sense of being compatible with the other ingredients, e.g., an MSI2 blocking compound, of the formulation and suitable for use in contact with the tissue or organ of a biological subject without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0214] Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginicacid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) alcohol, such as ethyl alcohol and propane alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations such as acetone.
[0215] The pharmaceutical compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like.434916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0216] In one embodiment, the pharmaceutically acceptable carrier is an aqueous carrier, e.g. buffered saline and the like. In certain embodiments, the pharmaceutically acceptable carrier is a polar solvent, e.g. acetone and alcohol.
[0217] The concentration of an MSI2 blocking compound in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the biological subject's needs. For example, the concentration can be about 0.0001% to 1%, 0.01 %-1%, 0.1 % to 1 %, 1 % to 50%, 1 % to 40%, 1 % to 30%, 1 % to 20%, 1 % to 10%, 1 % to 5%, 1 % to 4%, 1% to 3%, 1% to 2%, 50% to 100%, 40% to 50%, 30% to 40%, 20% to 30%, 10% to 20%, 5% to 10%, 6% to 10%, 7% to 10%, 8% to 10%, 9% to 10% by wt.
[0218] The compositions of the present disclosure can be administered for prophylactic, therapeutic, and / or hygienic use. Such administration can be topical, mucosal, e.g., oral, nasal, vaginal, rectal, parenteral, transdermal, subcutaneous, intramuscular, intravenous, via inhalation, ophthalmic and other convenient routes. The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include powder, tablets, pills, capsules and lozenges.
[0219] The compounds used in the method of the present invention can be administered in admixture with suitable pharmaceutical diluents, extenders, excipients, or in carriers such as the novel programmable sustained-release multi-compartmental nanospheres (collectively referred to herein as a pharmaceutically acceptable carrier) suitably selected with respect to the intended form of administration and as consistent with conventional pharmaceutical practices. The unit will be in a form suitable for oral, nasal, rectal, topical, intravenous or direct injection or parenteral administration. The compounds can be administered alone or mixed with a pharmaceutically acceptable carrier. This carrier can be a solid or liquid, and the type of carrier is generally chosen based on the type of administration being used. The active agent can be co-administered in the form of a tablet or capsule, liposome, as an agglomerated powder or in a liquid form. Examples of suitable solid carriers include lactose, sucrose, gelatin and agar. Capsule or tablets can be easily444916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 formulated and can be made easy to swallow or chew; other solid forms include granules, and bulk powders. Tablets may contain suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents. Examples of suitable liquid dosage forms include solutions or suspensions in water, pharmaceutically acceptable fats and oils, alcohols or other organic solvents, including esters, emulsions, syrups or elixirs, suspensions, solutions and / or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules. Such liquid dosage forms may contain, for example, suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, thickeners, and melting agents. Oral dosage forms optionally contain flavorants and coloring agents. Parenteral and intravenous forms may also include minerals and other materials to make them compatible with the type of injection or delivery system chosen.
[0220] A dosage unit of the compounds used in the method of the present invention may comprise a single compound or mixtures thereof with additional antibacterial agents. The compounds can be administered in oral dosage forms as tablets, capsules, pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. The compounds may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, or introduced directly, e.g. by injection, topical application, or other methods, into or onto a site of infection, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts.
[0221] Thus, a typical pharmaceutical composition for intravenous administration would be about 10’9g to about 100 g, about 10-6g to about 100 g, about 0.001 g to about 100 g, about 0.01 g to about 10 g, or about 0.01 g to about 1 g per subject per day. Dosages from about 0.01 mg, to about 5 g, per subject per day may be used. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pa. (1980).
[0222] An MSI2 blocking compound or a pharmaceutical composition thereof can be administered to a biological subject by any administration route known in the art, including454916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 without limitation, oral, enteral, buccal, nasal, topical, rectal, vaginal, aerosol, transmucosal, epidermal, transdermal, dermal, ophthalmic, pulmonary, subcutaneous, and / or parenteral administration. The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration.
[0223] A parenteral administration refers to an administration route that typically relates to injection which includes but is not limited to intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intra cardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, and / or intrasternal injection and / or infusion.
[0224] An MSI2 blocking compound or a pharmaceutical composition thereof can be given to a subject in the form of formulations or preparations suitable for each administration route. The formulations useful in the methods of the present disclosure include one or more MSI2 blocking compounds, one or more pharmaceutically acceptable carriers therefor, and optionally other therapeutic ingredients. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the subject being treated and the particular mode of administration. The amount of an MSI2 blocking compound which can be combined with a carrier material to produce a pharmaceutically effective dose will generally be that amount of an MSI2 blocking compound which produces a therapeutic effect or functional impact on tumor cells to effect a change capable of causing a therapeutic effect such as an anti-tumorigenic activity such as blocking / preventing tumor formation, or blocking / preventing growth of a tumor.
[0225] Methods of preparing these formulations or compositions include the step of bringing into association an MSI2 blocking compound with one or more pharmaceutically acceptable carriers and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association an MSI2 blocking compound with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.464916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0226] Formulations suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or nonaqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and / or as mouth washes and the like, each containing a predetermined amount of an MSI2 blocking compound as an active ingredient. A compound may also be administered as a bolus, electuary, or paste.
[0227] In solid dosage forms for oral administration (e.g., capsules, tablets, pills, dragees, powders, granules and the like), the MSI2 blocking compound is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and / or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginicacid, certain silicates, and sodium carbonate, (5) solution retarding agents, such as paraffin, (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
[0228] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable 474916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 machine a mixture of the powdered peptide or peptidomimetic moistened with an inert liquid diluent. Tablets, and other solid dosage forms, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of an MSI2 blocking compound therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and / or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain pacifying agents and may be of a composition that they release the MSI2 blocking compound(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The MSI2 blocking compound can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
[0229] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the MSI2 blocking compound, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
[0230] Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene 484916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water-soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.
[0231] Suspensions, in addition to the MSI2 blocking compound, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
[0232] Formulations for the topical ortransdermal or epidermal or dermal administration of an MSI2 blocking compound composition include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active component may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required. The ointments, pastes, creams and gels may contain, in addition to the MSI2 blocking compound composition, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Powders and sprays can contain, in addition to the MSI2 blocking compound composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
[0233] Transdermal patches can also be used to deliver MSI2 blocking compound compositions to a tumor site. Such formulations can be made by dissolving or dispersing the agent in the proper medium. Absorption enhancers can also be used to increase the flux of the MSI2 blocking compound across the skin. The rate of such flux can be controlled by494916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 either providing a rate controlling membrane or dispersing the MSI2 blocking compound in a polymer matrix or gel.
[0234] Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention.
[0235] Formulations suitable for parenteral administration comprise an MSI2 blocking compound in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacterostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
[0236] Examples of suitable aqueous and nonaqueous carriers which may be employed in the formulations suitable for parenteral administration include water, ethanol, polyols (e. g., such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
[0237] Formulations suitable for parenteral administration may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
[0238] Injectable depot forms are made by forming microencapsule matrices of a HPC or in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of the MSI2 blocking compound to polymer, and the nature of the particular polymer employed,504916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 the rate of drug release can be controlled. Examples of other biodegradable polymers include poly (orthoesters) and poly (anhydrides). Depot injectable formulations are also prepared by entrapping the MSI2 blocking compound in liposomes or microemulsions which are compatible with body tissue.
[0239] In certain embodiments, an MSI2 blocking compound, or a pharmaceutical composition thereof is delivered to a disease or tumor site in a therapeutically effective dose. As is known in the art of pharmacology, the precise amount of the pharmaceutically effective dose of an MSI2 blocking compound that will yield the most effective results in terms of efficacy of treatment in a given patient will depend upon, for example, the activity, the particular nature, pharmacokinetics, pharmacodynamics, and bioavailability of a particular MSI2 blocking compound, physiological condition of the subject (including race, age, sex, weight, diet, disease type and stage, general physical condition, responsiveness to a given dosage and type of medication), the nature of pharmaceutically acceptable carriers in a formulation, the route and frequency of administration being used, and the severity or propensity of a disease caused by pathogenic target microbial organisms, to name a few.
[0240] From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the scope of the invention. Accordingly, the invention is not limited except as by the appended claims.
[0241] Example 1 : Development of MicroScale Thermophoresis (MST) assay
[0242] A MicroScale Thermophoresis (MST) assay was developed to evaluate binding of compounds to MSI2 protein; conditions were established for the MST assay using MSI2 target RNA as a positive control. The instrument used for the MST (Dianthus) has two independent readout modes (TRIC, which detects the movement of the protein in solution, and Spectral Shift, which detects changes in the spectral emission of the label on the protein). A high concentration of MSI2 (20 nM) was used for the initial analysis, and significant binding was observed by MSI2 to the target RNA in both TRIC and Spectral Shift readout modes (Figure 1). To confirm MSI2-RNA binding under these conditions, a Tycho instrument was used to measure thermal stability of the protein. This analysis supported the 514916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 binding data generated in the MST assay, and showed that the target RNA binds and stabilizes MSI2 under the assay conditions, increasing its melting temperature by 4-4.5° C (Figure 2).
[0243] A dose titration MST experiment was then performed with a much lower concentration of MSI2 (2.5 nM) and the target RNA titrated down from 1 uM in 1:2 dilution steps. As shown in Figure 3, both TRIC and spectral shift readout modes showed low nanomolar binding, as expected given the affinity of the RNA for MSI2, with no change in initial fluorescence with increasing RNA (a measure of the “background” signal). Collectively, these data show that the MST assay effectively detects binding of the target RNA to MSI2.
[0244] The MST assay was validated by demonstrating binding of a known reference compound. For this, the tool compound (-) gossypol was used, which is known to bind to MSI2. As shown in Figure 4, some dose dependency and low pM binding of (-) gossypol was observed in the Spectral Shift readout mode. Binding in the TRIC readout mode was not detected, however, as binding of (-) gossypol may not induce enough of a conformational change to impact the movement of the protein. This underscores the importance of evaluating both readout modes when assessing the binding data. The MST assay was used in studies described below to confirm direct binding of promising compounds to MSI2.Example 2: Design, synthesis and profiling of modified hit compounds in TR-FRET and MST assays
[0245] One of the compounds, PCS2192 (WXHTS0063086), originally identified as a hit in the high throughput screen was pursued, and its activity was validated in dose response studies. PCS2192 was active in the TR-FRET assay (IC50 3.56 pM) and in the MST assay (IC50 12.6 pM, Figure 5) after being freshly resynthesized, and was subsequently advanced for testing in murine and human pancreatic cancer tumorsphere assays and structure-activity relationship (SAR) exploration (below). Very promising data has been obtained with this compound, which has developed into a lead series as disclosed herein.524916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0246] Based on the structure of PCS2192, six new compounds were designed for custom synthesis to explore SAR. The structures of these six compounds as well as PCS2192 are shown above and in FIG. 9. These compounds (synthesized at PharmaBlock) were then tested in biochemical and biophysical assays:
[0247] The activity of the six compounds in TR-FRET were:PCS3380 (16uM)PCS3381 (17uM)PH01629269 (10.3uM)PCS3152 (0.8uM)PCS3375 (1.7uM)PBUE231 (14.3 uM)
[0248] The structures of these compounds are shown above. Notably, two of the newly designed compounds (PCS3152 and PCS3375) had TR-FRET IC50s that were lower than those of the parent compound (PCS2192).
[0249] Three of the most potent new compounds were then tested in MST and found to directly bind MSI2. The structures of these compounds are shown above:PCS3152 (0.44uM)PCS3375 (2uM)PBUE231 (32.5uM)
[0250] As with the TR-FRET assay, both PCS3152 and PCS3375 had MST IC50s that were lower than those of the parent compound (PCS2192).
[0251] The conformation-driven approach disclosed herein has led to the identification of a new series of compounds with promising therapeutic potential. These compounds represent the identification of a lead series that includes novel compounds that bind MSI2 (demonstrated through the MST assay) and inhibit the binding of MSI2 to target RNA (demonstrated through the TR-FRET assay). Several of these compounds were advanced for profiling in in vitro ADME assays as well as testing in murine and human tumorsphere assays and in PK studies (see below).
[0252] Example 3: Profiling of potent compounds in in vitro ADME assays534916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0253] To advance the studies discussed above, the original hit PCS2192 and the leading structural derivative, PCS3152, were chosen for an Absorption, Distribution, Metabolism, and Excretion (ADME) study to understand their physicochemical properties. This information will serve as a valuable guide for further optimization. The compounds were tested in a panel of in vitro ADME assays to aid in further prioritization. These studies included assays of kinetic solubility, plasma protein binding, lipid-PAMPA, Caco2 bidirectional, CYP phenotyping, stability in liver microsomes, and hERG assay.
[0254] Table 1 illustrates the ADME properties of the two compounds, indicating their robust solubility and favorable plasma protein binding. Both compounds exhibit good stability in Liver Microsomes (LM) for both human and mouse species, with PCS2192 demonstrating superior stability in LM. Notably, in the Caco2 permeability assay, PCS2192 displays exceptional permeability without any observed efflux issues. In comparison, PCS3152 exhibits relatively lower permeability and a discernible efflux ratio. Nevertheless, the permeability of PCS3152 remains within an acceptable range.544916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0255] Table 1. ADME Summary of PCS2192 and PCS3152i \ IPCS2192 PCS3152 Solubility (uM) PBS (pH 7.4) 302.18 297.20A-B Papp (10-6 cm / sec) 25.23 2.05 Caco2 B-A Papp (10-6 cm / sec) 8.74 7.26 PermeabilityEfflux Ratio 0.35Human 97.54 94.30 PPB(H) Rat 94.93 91.62Mouse 93.14 80.59 Liver Microsomes Human <5.42 5.67 CLint (pL / min / mg protein) Mouse <5.42 8.50Example 4: Testing active compounds in murine and human pancreatic cancer tumorsphere assays
[0256] The lead series was tested in murine and human tumorsphere assays. This included the original hit,PCS2192, and two of the newly designed structural derivatives of this compound that were active in the TR-FRET and MST assays, PCS3152 and PBUE231. The impact of these compounds was tested on the sphere forming ability of KPC-derived tumor cells as well as a human pancreatic cancer cell line (FG) and prim Ina (n-ry patient-derived organoids. Compounds were tested over a range of concentrations (15-90 pM), spheres were counted 7-10 days later, and impact was determined relative to vehicle-treated controls. Importantly, each of the compounds significantly reduced tumorsphere formation in each of the tumor cell types tested (Figures 6-8). These findings are promising because they demonstrate that the newly designed compounds have a significant functional impact on pancreatic cancer cells, including anti-tumorigenic activity that may be useful for blocking / preventing formation of a tumor, blocking / preventing growth of a tumor, or for treating or inducing regression of a tumor.554916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 Example 5: Testing top cell-active compounds in single concentration pharmacokinetic (PK) assay in mice, two routes [intravenous (IV) and oral]
[0257] The Single-Dose Pharmacokinetics (SDPK) was assessed in mice for the leading compound, PCS3152, to explore its potential as a drug candidate.
[0258] The SDPK data for compound PCS3152 (summarized in Table 2) indicates outstanding bioavailability, reasonable Vss, good clearance, and acceptable AUC. The initial SDPK data suggests the viability of this compound series.
[0259] Table 2. SDPK Summary of compound PCS3152Table 2. SDPK Summary of compound PCS3152Cyml / WrsAg) 29.9L..z (hr) 033?IV J tnpk .(Meuse) Vt(l / kg)AO * eg / ml) S670.250ng / ml) 3523POJOmpk4243(Meuse)Txzdhr) 1.00H%) 74,1
[0260] The novel compounds that have been designed thus serve as a promising starting point for further exploration for additional compounds and derivatives.
[0261] Example 6: Generation of Dual Conditional Knockout Mice
[0262] To test the impact of global MSI1 / MSI2 inhibition in healthy adult mice, dual MSI1 / MSI2 conditional knockout mice (mice that carry the RosaCreER allele and are homozygous for the Msi1 / Msi2 floxed alleles) were generated. To these knockout mice were4916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 delivered tamoxifen to trigger deletion of the Msi1 and Msi2 genes in all tissues, and the impact of the dual loss of Msi1 and Msi2 in adult mice was determined.
[0263] Cohorts of 3 adult mice were treated with either tamoxifen (150 mg / kg) or vehicle (corn oil) daily for 5 days to induce deletion of Msi1 and Msi2. After a month, these were submitted to the Histopathology and Comparative Pathology Facility at the Albert Einstein College of Medicine for necropsy and comprehensive histopathology analysis of all tissues.
[0264] Histologic findings in all animals were minimal and were not considered to be of clinical significance. This result suggests limited potential safety liabilities even if inhibitors developed to target MSI2 may also have significant activity against MSI1.
[0265] Example 7 - Cellular Thermal Shift Assay (CETSA)
[0266] To test whether the inhibitors bind MSI2 within a physiologically relevant cellular environment, a Cellular Thermal Shift Assay (CETSA) was established. CETSA directly measures compound-induced protein stabilization inside intact cells or cell lysates based on the principle that ligand binding increases the thermal stability of a target protein. Upon incremental heating, unbound proteins denature and precipitate, while ligand-bound proteins remain soluble. The relative amount of soluble protein at each temperature is then quantified, typically using western blotting or homogeneous immunoassays (Fig. 10). The CETSA enables calculation of the apparent aggregation temperature (Tagg) or construction of isothermal dose-response curves to confirm target-binding within cells. By measuring target engagement in the native cellular context, CETSA avoids artifacts related to protein overexpression or artificial purification and provides a robust indicator of compound activity and bioavailability.
[0267] A CETSA was performed with HEK-293T cells that were treated with DMSO or increasing concentrations of the lead parent compound, PCS2192, from 20 pM to 100 pM. As shown in Figs. 11-14 the level of soluble MSI2 increased in a dose-dependent manner at 48°C and 50°C. These data suggest direct intracellular binding between MSI2 and PCS2192, leading to stabilization of the MSI2 protein.574916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0268] Luciferase Reporter Assay
[0269] A 3’-UTR reporter LightSwitch assay (Active Motif, Inc.) was established to test the ability of lead inhibitors to block MSI2 activity in living cells. The assay utilizes a luciferase reporter gene linked to the 3’UTR of the Numb transcript (“Luciferase-Numb 3’-UTR”). Numb is regulated by MSI2: binding of MSI2 to the 3’UTR of the Numb transcript represses its translation. Thus, expression of luciferase from the Luciferase-Numb 3’-UTR construct is blocked in the presence of MSI2. However, when MSI2 activity is blocked by an inhibitor, it will not be able to bind the Numb 3’-UTR and luciferase will be produced, leading to an increase in luminescence compared to controls (Fig. 15).
[0270] PCS2192 was tested in the LightSwitch Assay. HEK-293T cells were transfected with Luciferase-Numb 3’-UTR reporter plasmid and treated with DMSO or PCS2192 (20-100 uM). Luminescence was normalized to cell viability and fold change was calculated relative to the results from DMSO-treated samples. As shown in Fig. 16, treatment with PCS2192 led to a significant increase in the luminescence signal. Next, we tested one of the novel compounds we designed, PCS3375, in the LightSwitch assay. HEK-293T cells were transfected with Luciferase-Numb 3’-UTR reporter plasmid and treated with DMSO or PCS3375 (20-100 uM). As shown in Fig. 17, treatment with PCS3375 also led to an increase in the luminescence signal. These data suggest on-target binding between PCS2192 / PCS3375 and MSI2 within living cells.
[0271] Collectively, the CETSA and luciferase reporter assays demonstrate that the parent compound and at least one derivative in the lead series can effectively engage and block MSI2 activity intracellularly.
[0272] Example 8 - PROTACs:
[0273] To further improve flexibility of the inhibitors of MSI2 disclosed herein, PROTACs comprising the inhibitors can be constructed. The following tables illustrate nonlimiting exemplary Linkers, E3 ligase ligands, building blocks (linker+E3 ligase ligand), and complete PROTACs (building block + any compound disclosed herein, e.g. as an example compound PCS3375). POI ligand is “protein of interest” ligand.584916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0274] Table 3 - exemplary linkers:LinkersLigandAlkyl(Cn)-amine Ligand LigasenNHAlkyl(Cn)«carboxylic acid Ligand Ligase '^'POI Ligand0 / '°\PEG(n)-carboxylic acid Ligand Ligase £:?pot L'Sanc*0 / \ «PEG(n)»amineLigand Ligase £ / '' C^" '"'POi Ligand4916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0275] Table 4: Exemplary E3 ligase ligands:E3 Ligase LigandsPomalidomideOvLenalidomidet( rThalidomideX >VH 032< I604916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0276] Table 5: Exemplary PROTAC building blocks:SkK&m# blocks614916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710
[0277] Table 6: Exemplary PROTACs:Complete PROTACsI624916-6765-7898v.l
Claims
Atty Docket No. 92573-A-PCT 93597 / 7710 CLAIMS1. A Musashi 2 (MSI2) blocking compound ofFormula IAor stereoisomer, ester, or salt thereof,or of Formula IBor stereoisomer, ester, or salt thereof,wherein R2is selected from the group consisting of hydrogen, a C1-6 alkyl, a cycloakyl, a heterocycloalkyl, an aryl, or a heteroaryl, wherein the nonhydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxyl or carboxylate group, and a thio group.634916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 2. The MSI2 blocking compound of claim 1, wherein the compound isor stereoisomer, ester, or salt thereof, or3. A Musashi 2 (MSI2) blocking compound of Formula IICH3 or stereoisomer, ester, or salt thereof wherein any one or more of R3, R4, R5, R6, or R7can be C, CH, or N; and wherein R8is selected from the group consisting of hydrogen, a C1-6 alkyl, a cycloakyl, a heterocycloalkyl, an aryl, or a heteroaryl, wherein the nonhydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxyl or carboxylate group, and a thio group.644916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 4. The MSI2 blocking compound of claim 3, comprising a MSI2 blocking compound of Formula HACH3 or stereoisomer, ester, or salt thereof, wherein R8is selected from the group consisting of hydrogen, a C1-6 alkyl, a cycloakyl, a heterocycloalkyl, an aryl, or a heteroaryl, wherein the nonhydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxyl or carboxylate group, and a thio group.
5. The MSI2 blocking compound of claim 4, wherein the compound isCH3OH CH3or stereoisomer, ester, or salt thereof, oror stereoisomer, ester, or salt thereof,654916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 CH3CH3N'NH or stereoisomer, ester, or salt thereof.
6. The MSI2 blocking compound of claim 3, further comprising a MSI2 blocking compound of Formula IIBCH3•NI N NCH3or stereoisomer, ester, or salt thereof, wherein R8is selected from the group consisting of hydrogen, a C1-6 alkyl, a cycloakyl, a heterocycloalkyl, an aryl, or a heteroaryl, wherein the nonhydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxyl or carboxylate group, and a thio group.
7. The MSI2 blocking compound of claim 6, wherein the compound isCH3N I OH NCH3or stereoisomer, ester, or salt thereof.4916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 8. The MSI2 blocking compound of claim 3, further comprising a MSI2 blocking compound of Formula IICCH3zNNZNCH3or stereoisomer, ester, or salt thereof, wherein R8is selected from the group consisting of hydrogen, a C1-6 alkyl, a cycloakyl, a heterocycloalkyl, an aryl, or a heteroaryl, wherein the nonhydrogen groups are optionally substituted by one or more substituents selected from a carbonyl group, a carboxyl or carboxylate group, and a thio group.
9. The MSI2 blocking compound of claim 8, wherein the compound isCH3N OHNCH3or stereoisomer, ester, or salt thereof.
10. A pharmaceutical composition comprising the MSI2 blocking compound of any one of claims 1 to 9, or stereoisomer, ester, or salt thereof, and a carrier.
11. The use of the MSI2 blocking compound of any one of claims 1 to 9, or stereoisomer, ester, or salt thereof, for the treatment of a cancer.
12. A method of treating a cancer comprising administering a administering the MSI2 blocking compound of any one of claims 1 to 9, or stereoisomer, ester, or salt thereof, to a subject.4916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 13. The use or method of claim 11 or 12, wherein the cancer is pancreatic cancer, ovarian cancer, breast cancer, lung cancer, colorectal cancer, malignant glioma, hepatic cancer, prostate cancer, bladder cancer, oral or esophageal cancer, gastric cancer, thyroid cancer, or a hematological malignancy.
14. The use or method of any one of claims 11 to 13, wherein the MSI2 blocking compound, or stereoisomer, ester, or salt thereof, is part of a pharmaceutical composition.
15. A method for blocking or reducing the formation of a tumor comprising contacting a tumor cell or a population of tumor cells with the MSI2 blocking compound of any one of claims 1 to 9, or stereoisomer, ester, or salt thereof.
16. A method for blocking or reducing the growth of a tumor comprising contacting a tumor cell or a population of tumor cells with the MSI2 blocking compound of any one of claims 1 to 9, or stereoisomer, ester, or salt thereof.
17. A method for inducing regression of a tumor comprising contacting a tumor cell or a population of tumor cells with the MSI2 blocking compound of any one of claims 1 to 9, or stereoisomer, ester, or salt thereof.
18. The methods of any one of claims 15 to 17, wherein the tumor cell or population of tumor cells are pancreatic cancer cells, ovarian cancer cells, breast cancer cells, lung cancer cells, colorectal cancer cells, malignant glioma cells, hepatic cancer cells, prostate cancer cells, bladder cancer cells, oral or esophageal cancer cells, gastric cancer cells, thyroid cancer cells, or cells of a hematological malignancy.
19. The method of any one of claims 15 to 18, wherein the MSI2 blocking compound, or stereoisomer, ester, or salt thereof, is part of a pharmaceutical 684916-6765-7898v.lAtty Docket No. 92573-A-PCT 93597 / 7710 composition.
20. A PROTAC as set forth in Table 6.694916-6765-7898v.l
